The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Eli Lilly remains a top stock to buy and hold. Vertex Pharmaceuticals is moving quickly to expand its markets beyond cystic ...

People taking weight loss drugs typically start to lose weight within a few weeks. One study, funded by Mounjaro manufacturer ...

With semaglutide patents set to expire in 2026, Indian pharma giants are ramping up peptide production and device tie-ups to ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

Equities extended their July advance, with the S&P 500 set for its longest streak of monthly gains since September.

Novo Nordisk has reported another significant criticality: the presence of unauthorized versions of its drugs on the US ...

Farm and construction equipment maker CNH Industrial expects a muted finish to the year due to tariff impacts, despite posting second-quarter results above expectations on Friday. The effects will ...